Celcuity Q2 2023 Earnings Report

Reported financial results for the second quarter ended June 30, 2023 and provided other recent corporate updates.

Key Takeaways

Celcuity reported a net loss of $14.6 million, or $0.66 loss per share, for the second quarter of 2023, compared to a net loss of $10.0 million, or $0.67 loss per share, for the second quarter of 2022. Total operating expenses were $15.1 million, and research and development expenses were $13.7 million. Cash, cash equivalents and short-term investments totaled $146.2 million at the end of the quarter.

Patient enrollment in the Phase 3 VIKTORIA-1 trial is progressing in-line with planned timeline.

Nearly 200 sites are now recruiting patients in 20 countries for the VIKTORIA-1 trial.

Updated median PFS and DOR data for gedatolisib in combination with letrozole and palbociclib in the first-line setting were reported.

Confidence remains high that gedatolisib can improve outcomes for women with HR+/HER2- advanced breast cancer, regardless of PIK3CA-status.

EPS

-$0.58

Previous year: -$0.55

+5.5%

Cash and Equivalents

$146M

Previous year: $66.9M

+118.5%